Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

Published:2018-05 Issue:5 Volume:29 Page:1235-1248
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Sydes M.R.^ORCID,Spears M.R.,Mason M.D.,Clarke N.W.,Dearnaley D.P.,de Bono J.S.,Attard G.^ORCID,Chowdhury S.,Cross W.,Gillessen S.,Malik Z.I.,Jones R.,Parker C.C.,Ritchie A.W.S.,Russell J.M.,Millman R.,Matheson D.,Amos C.,Gilson C.,Birtle A.,Brock S.,Capaldi L.,Chakraborti P.,Choudhury A.,Evans L.,Ford D.,Gale J.,Gibbs S.,Gilbert D.C.^ORCID,Hughes R.,McLaren D.,Lester J.F.,Nikapota A.,O’Sullivan J.,Parikh O.,Peedell C.,Protheroe A.,Rudman S.M.,Shaffer R.,Sheehan D.,Simms M.,Srihari N.,Strebel R.,Sundar S.,Tolan S.,Tsang D.,Varughese M.,Wagstaff J.,Parmar M.K.B.,James N.D.

Funder

Cancer Research UK

Medical Research Council

NIHR

Institute of Cancer Research

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/5/1235/25083238/mdy072.pdf

Reference25 articles.

1. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial;Widmark;Lancet,2009

2. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer;Mason;JCO,2015

3. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial;Mottet;Eur Urol,2012

4. A phase III trial of docetaxel–estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial;Fizazi;Eur J Cancer,2012

5. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial;Fizazi;Lancet Oncol,2015

Cited by 205 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanomedicines in diagnosis and treatment of prostate cancers: an updated review;Frontiers in Bioengineering and Biotechnology;2024-08-21

2. Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial;Nature Medicine;2024-08-20

3. Japanese clinical practice guidelines for prostate cancer 2023;International Journal of Urology;2024-07-30

4. Effect of Radical Prostatectomy on Survival for Men with High-risk Nonmetastatic Prostate Cancer Features Selected According to STAMPEDE Criteria: An EMPaCT Study;European Urology Oncology;2024-07

5. Efficacy and safety of triple or dual therapies for metastatic hormone-sensitive prostate cancer: a systematic review and Bayesian network meta-analysis;Future Oncology;2024-06-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3